BEDFORD, Mass., May 13, 2014 /PRNewswire/ -- Hologic, Inc.
(Hologic or the Company) (NASDAQ: HOLX), a leading developer,
manufacturer and supplier of premium diagnostic products, medical
imaging systems and surgical products, with an emphasis on serving
the healthcare needs of women, today announced that Robert W. McMahon has been appointed Chief
Financial Officer, effective May 26,
2014.
Mr. McMahon joins Hologic with more than 20 years of financial
leadership experience. He previously held a number of senior
positions at Johnson & Johnson, most recently serving as
Worldwide Vice President of Finance and Business Development for
the Ortho Clinical Diagnostics group.
Mr. McMahon succeeds Glenn Muir,
who is retiring as the Company's Chief Financial Officer, as
previously announced on March 14,
2014. Mr. Muir will remain with the Company through
November 30, 2014 to help ensure a
smooth transition.
"Bob has an established track record leading global finance
organizations and he will significantly strengthen our executive
team," said Stephen MacMillan,
President and Chief Executive Officer. "Bob's strong operational
experience will play an important role as we are repositioning our
organization to focus on organic growth via stronger executional
discipline. We are building a winning team and Bob brings core
skills and leadership capabilities that will help improve our
performance."
Hologic also announced today that it has appointed Peter J. Valenti III as Division President,
Breast Health, effective May 26,
2014. Mr. Valenti joins Hologic with nearly 30 years of
sales, brand and product management experience, including 20 years
focused on healthcare products. Mr. Valenti will also have overall
responsibility for the Company's Skeletal Health division.
"Peter is a welcomed addition to the team as part of the new
leadership structure," said Stephen
MacMillan. "Our enhanced senior leadership team is squarely
focused on accelerating organic growth, improving our operating and
financial performance, and continuing to deliver the best solutions
for our customers. Peter's track record of accelerating growth in
businesses combined with his strong marketing background will be an
important addition to our organization."
About Robert W.
McMahon:
Robert W. McMahon is a proven
business executive with a demonstrated track record of success. An
industry veteran with more than 20 years of healthcare finance
experience, Mr. McMahon worked at Johnson & Johnson from 1993
to 2014, in executive finance roles of increasing responsibility.
Most recently, he served as the Worldwide Vice President, Finance
and Business Development, Ortho Clinical Diagnostics for Johnson
& Johnson. In this position, he was responsible for the
financial leadership and oversight of a $1.9
billion business. From 2006 to 2011, he served as Vice
President, Finance, Consumer Group and from 2004 to 2006 he served
as Vice President, Finance, Networking & Computing Services. He
is a Certified Management Accountant and holds a Masters of
Business Administration from the University of
Central Florida and a Bachelor of Science in Business
Administration from the University of Florida.
About Peter J. Valenti
III:
Peter J. Valenti III is a
seasoned industry veteran with nearly 30 years of sales, brand and
product management experience, including 20 years focused on
healthcare products. His track record includes successful
turnarounds of global businesses and establishing and executing on
portfolio strategies that helped maximize growth. Most recently,
Mr. Valenti was a Principal at The New England Consulting Group
where he served as a consultant to numerous healthcare companies,
including Bausch + Lomb Inc., a role he assumed following his
four-year tenure in the North American and Global President roles
of Bausch + Lomb's Vision Care business. Prior to these roles, Mr.
Valenti was the General Manager, U.S. Region for Covidien's
Surgical Devices business. Previously, Mr. Valenti spent 12 years
with Johnson & Johnson and held positions of increasing
responsibility including Vice President, Global Franchise for the
Vistakon business and Executive Director, Women's Health for
Johnson & Johnson's Personal Products business. He began his
career at Procter & Gamble. He received a Masters of Business
Administration from Cornell University
and a Bachelor of Science in Business Administration from the
University of Connecticut.
About Hologic, Inc.:
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems, and
surgical products, with an emphasis on serving the healthcare needs
of women. The Company operates four core business units focused on
breast health, diagnostics, GYN surgical and skeletal health. With
a comprehensive suite of technologies and a robust research and
development program, Hologic is committed to improving lives. The
Company is headquartered in Massachusetts. For more information, visit
www.hologic.com.
Forward-Looking Statement Disclaimer:
This News Release contains forward-looking information that
involves risks and uncertainties, including statements about the
Company's plans, objectives, expectations and intentions. Such
statements include, without limitation: the Company's positioning,
resources, capabilities, and expectations for future performance,
growth and shareholder value. These forward-looking statements are
based upon assumptions made by the Company as of the date hereof
and are subject to known and unknown risks and uncertainties that
could cause actual results to differ materially from those
anticipated.
Risks and uncertainties that could adversely affect the
Company's business and prospects, and otherwise cause actual
results to differ materially from those anticipated, include
without limitation: the ability to successfully manage ongoing
organizational changes, including the ability of the Company to
successfully attract, motivate and retain key employees; U.S.,
European and general worldwide economic conditions and related
uncertainties; the Company's reliance on third-party reimbursement
policies to support the sales and market acceptance of its
products, including the possible adverse impact of government
regulation and changes in the availability and amount of
reimbursement and uncertainties for new products or product
enhancements; uncertainties regarding the recently enacted or
future healthcare reform legislation, including associated tax
provisions, or budget reduction or other cost containment efforts;
changes in guidelines, recommendations and studies published by
various organizations that could affect the use of the Company's
products; uncertainties inherent in the development of new products
and the enhancement of existing products, including FDA approval
and/or clearance and other regulatory risks, technical risks, cost
overruns and delays; the risk that products may contain undetected
errors or defects or otherwise not perform as anticipated; risks
associated with acquisitions, including without limitation, the
Company's ability to successfully integrate acquired businesses,
the risks that the acquired businesses may not operate as
effectively and efficiently as expected even if otherwise
successfully integrated, the risks that acquisitions may involve
unexpected costs or unexpected liabilities; the risks of conducting
business internationally, including the effect of exchange rate
fluctuations on those operations; manufacturing risks, including
the Company's reliance on a single or limited source of supply for
key components, and the need to comply with especially high
standards for the manufacture of many of its products; the
Company's ability to predict accurately the demand for its
products, and products under development, and to develop strategies
to address its markets successfully; the early stage of market
development for certain of the Company's products; the Company's
leverage risks, including the Company's obligation to meet payment
obligations and financial covenants associated with its debt; risks
related to the use and protection of intellectual property;
expenses, uncertainties and potential liabilities relating to
litigation, including, without limitation, commercial, intellectual
property, employment and product liability litigation; technical
innovations that could render products marketed or under
development by the Company obsolete; and competition.
The risks included above are not exhaustive. Other factors that
could adversely affect the Company's business and prospects are
described in the filings made by the Company with the SEC. The
Company expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any such statements
presented herein to reflect any change in expectations or any
change in events, conditions or circumstances on which any such
statements are based.
Contacts:
Deborah R. Gordon
Vice President, Investor Relations and
Corporate
Communications
(781)
999-7716
deborah.gordon@hologic.com
|
Al Kildani
Senior Director, Investor Relations
(858) 410-8653
al.kildani@hologic.com
|
SOURCE Hologic, Inc.